KRMD
KORU Medical Systems, Inc.
KRMD has the edge over NVO overall, supported by stronger fundamentals.
NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
KRMD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Strong |
KRMD's revenue and balance sheet are currently healthy, and its profitability is stable, but its cash flow is under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
KRMD PE Valuation
KRMD has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 226x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
KRMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
KRMD has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
KRMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.02 | — |
| Q3 2026 | -$0.02 | +$0.07 |
| Q2 2026 | -$0.04 | +$0.06 |
| Q1 2026 | -$0.05 | +$0.07 |
| Q4 2025 | -$0.06 | +$0.07 |
| Q3 2025 | -$0.09 | +$0.17 |
| Q2 2025 | -$0.10 | +$0.16 |
| Q1 2025 | -$0.12 | +$0.17 |
| Q4 2024 | -$0.13 | +$0.17 |
KRMD is still losing money, but far less than before: $0.02 per share over the past year, against $0.30 at its worst in late 2023.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over KRMD on earnings quality, reporting a profit while its opponent remains loss making.
KRMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.6M | +11% |
| Q2 2026 | $12M | +18% |
| Q1 2026 | $11.8M | +22% |
| Q4 2025 | $10.9M | +23% |
| Q3 2025 | $10.4M | +27% |
| Q2 2025 | $10.2M | +21% |
| Q1 2025 | $9.6M | +18% |
| Q4 2024 | $8.8M | +23% |
KRMD has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.6% | +10 points |
| Q2 2026 | 5.2% | +8.3 points |
| Q1 2026 | -7.3% | +5.6 points |
| Q4 2025 | -5% | +13 points |
| Q3 2025 | -8.3% | +13 points |
| Q2 2025 | -3.1% | +11 points |
| Q1 2025 | -13% | +11 points |
| Q4 2024 | -18% | +13 points |
KRMD's operating margin was 1.6% last quarter, up 10 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over KRMD on profitability, with a higher operating margin.
KRMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2M | -8973% |
| Q2 2026 | $108.2K | +$597.4K |
| Q1 2026 | -$31.5K | +$649.4K |
| Q4 2025 | $687K | -30% |
| Q3 2025 | $13K | +$2M |
| Q2 2025 | -$489.2K | -$376.2K |
| Q1 2025 | -$680.9K | -$201.1K |
| Q4 2024 | $983.2K | +9.2% |
KRMD has burned cash in most quarters: −$387,369 over the past year, against −$173,904 the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over KRMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
KRMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.6% | -2.8M shares |
| 1 year | +1.1% | +493K shares |
| 3 years | +2.4% | +1.1M shares |
| 5 years | +5.4% | +2.4M shares |
| Available history | +20% | +7.7M shares |
KRMD has 47M diluted shares, up 1.1% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over KRMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
KRMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -37.0x | Net Cash |
| Q3 2020 | -239.5x | Net Cash |
| Q2 2020 | -60.9x | Net Cash |
| Q1 2020 | -3.6x | Net Cash |
| Q4 2019 | -6.3x | Net Cash |
KRMD has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
KRMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.0 | Neutral |
| Stochastic | 30.9 | Neutral |
KRMD's weekly RSI is 53 (neutral) and its Stochastic is 31 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
KRMD PE vs Healthcare Sector
| Metric | KRMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
KRMD has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
KRMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.13 | 18% above |
| 20 week MA | $3.45 | 7% above |
| 50 week MA | $4.20 | 12% below |
| 100 week MA | $3.92 | 5.9% below |
| 200 week MA | $3.39 | 8.8% above |
KRMD has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
KRMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $6.15 | $6.09 | -1% |
| 2021 | $6.09 | $3.25 | -47% |
| 2022 | $3.25 | $3.42 | +5.2% |
| 2023 | $3.42 | $2.46 | -28% |
| 2024 | $2.46 | $3.94 | +60% |
| 2025 | $3.94 | $6.23 | +58% |
| 2026 YTD | $6.23 | $3.69 | -41% |
KRMD has finished lower in three of the last six years. It's down 41% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over KRMD on returns for 2026, with the stronger performance.